Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M640Revenue (TTM) $M28.2Net Margin (%)-584.8Altman Z-Score-6.3
Enterprise Value $M650EPS (TTM) $-1.6Operating Margin %-404.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score65.0Pre-tax Margin (%)-584.5Higher ROA y-yN
Price/Book29.910-y EBITDA Growth Rate %--Quick Ratio7.4Cash flow > EarningsY
Price/Sales23.15-y EBITDA Growth Rate %29.5Current Ratio8.8Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-80.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-243.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M106ROIC % (ttm)-379.9Gross Margin Increase y-yN

Gurus Latest Trades with KERX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
KERXJoel Greenblatt 2016-09-30 Sold Out -0.01%$4.1 - $7.53
($5.39)
$ 6.0412%Sold Out0
KERXJoel Greenblatt 2016-06-30 Add0.01%$4.54 - $6.76
($5.58)
$ 6.048%Add 206.30%77,976
KERXJoel Greenblatt 2016-03-31 Buy $3.17 - $5.38
($3.99)
$ 6.0451%New holding25,457
KERXSeth Klarman 2015-06-30 Add0.57%$9.32 - $12.73
($10.75)
$ 6.04-44%Add 15.24%25,791,678
KERXSeth Klarman 2015-03-31 Add0.88%$10.87 - $14.68
($12.86)
$ 6.04-53%Add 22.30%22,380,200
KERXSeth Klarman 2014-09-30 Add1.87%$12.71 - $18.19
($15.32)
$ 6.04-61%Add 73.62%18,300,000
KERXSeth Klarman 2014-06-30 Add1.04%$12.11 - $17.03
($14.16)
$ 6.04-57%Add 67.01%10,539,986
KERXSeth Klarman 2014-03-31 Buy 2.6%$12.16 - $16.88
($14.98)
$ 6.04-60%New holding6,310,850
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

KERX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


KERX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Madison GregPresident and CEO 2016-11-09Sell1,559$4.9918.24view
Holmes Scott ACFO 2016-10-28Sell1,237$4.4432.88view
Neylan John F.Chief Medical Officer 2016-10-24Sell1,211$4.7225view
Adams BrianVP and General Counsel 2016-10-17Sell1,106$4.8621.4view
Madison GregPresident and CEO 2016-10-05Sell917$5.389.67view
Adams BrianVP and General Counsel 2016-10-05Sell647$5.389.67view
Madison GregPresident and CEO 2016-08-09Sell1,622$4.2239.81view
Madison GregPresident and CEO 2016-08-09Sell1,622$4.2239.81view
Holmes Scott ACFO 2016-07-29Sell4,935$7.36-19.84view
Neylan John F.Chief Medical Officer 2016-07-25Sell1,217$7.43-20.59view

Quarterly/Annual Reports about KERX:

News about KERX:

Articles On GuruFocus.com
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 12 2016 
Klarman Gives Insight on Keryx Biopharmaceuticals Investment Jan 26 2016 
Seth Klarman Blames Market, Investments for Rare Down Year Jan 25 2016 
David Abrams Buys Stake in Heavy Equipment Company Dec 15 2015 
Why Seth Klarman Keeps Buying Keryx Biopharma Nov 03 2015 
Seth Klarman Raises Position in Keryx Biopharmaceuticals Oct 21 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Is Seth Klarman right about Keryx Inc.? Jun 25 2015 
Seth Klarman Buys Pioneer Natural Resources, SunEdison Semiconductor Ltd, Atara Biotherapeutics Inc, May 15 2015 
Analysts Positive on Keryx Biopharmaceuticals, Inc. Despite Weak Prescription Data May 05 2015 

More From Other Websites
ETFs with exposure to Keryx Biopharmaceuticals, Inc. : December 5, 2016 Dec 05 2016
ETFs with exposure to Keryx Biopharmaceuticals, Inc. : November 23, 2016 Nov 23 2016
Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21,... Nov 21 2016
Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASN’s Kidney Week Nov 18 2016
Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASN’s Kidney Week Nov 18 2016
Keryx (KERX) Stock Up on Positive Phase III Auryxia Data Nov 18 2016
KERYX BIOPHARMACEUTICALS INC Financials Nov 17 2016
Keryx Biopharmaceuticals Announces Multiple Scientific Presentations of Phase 3 Trial Results of... Nov 17 2016
Keryx (KERX) Q3 Loss Wider than Expected, Restores Supply Nov 10 2016
​FDA action helps Keryx move past drug supply snafu Nov 10 2016
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events Nov 09 2016
Edited Transcript of KERX earnings conference call or presentation 9-Nov-16 1:00pm GMT Nov 09 2016
ETF’s with exposure to Keryx Biopharmaceuticals, Inc. : November 9, 2016 Nov 09 2016
Keryx Biopharma upgraded by Maxim Group Nov 09 2016
Keryx Biopharmaceuticals Announces U.S. FDA Approval of Second Contract Manufacturer for Auryxia®... Nov 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)